Background: The aim of the present study was to evaluate safety and efficacy of Sri Sri TattvaTM immunity products, a combination of single herb and poly herb formulations in COVID-19 patients by assessing their clinical features and immune markers. The products when administered orally for a period of 14 days in COVID-19 patients demonstrated significant improvement in clinical symptoms.Methods: Patients with fever, cough, sore throat started responding to the treatment from day 3 and most of the patients were clinically free of symptoms by day 7. Early recovery from signs and symptoms was observed in most of the patients. Sri Sri TattvaTM immunity products has also demonstrated an excellent clinical improvement and immune markers including tumor necrosis factor (TNF-alfa), interleukin (IL-6), interferon (IFN-beta), D-dimer, ferritin, lactate dehydrogenease (LDH) and C-reactive protein (CRP) in COVID-19 patients.Results: The final results of this study showed that Sri Sri TattvaTM immunity products reduced the time to clinical cure and number of days in achieving negative real time polymerase chain reaction (RT-PCR) by early viral clearance when given along with standard of care thus reduced the duration of hospitalization.Conclusions: In the present study, 82% of COVID-19 patients cleared the virus within 10-14 days of study period reducing the duration of hospitalization. None of the patients progressed to severe COVID-19 and succumbed to the disease. This clearly indicates that Sri Sri TattvaTM immunity products when administered orally along with standard of care has definitive role in the management of COVID-19 patients.
Background: We tested if tele-yoga intervention could aid in better clinical management for hospitalized patients with mild to moderate COVID-19 when complemented with the standard of care.Methods: This was a randomized controlled trial conducted at the Narayana Hrudalaya, Bengaluru, India on hospitalized patients with mild to moderate COVID-19 infection, enrolled between May 31st and July 22, 2021. Patients (n=225) were randomized in 1:1 ratio [adjunct tele-yoga (n = 113), or standard of care (n = 112)]. Adjunct yoga group received intervention in tele-mode within 4 hours post-randomization until 14 days along with the standard of care. The primary outcome was clinical status at 14th-day post-randomization assessed with a 7-category ordinal scale. The trial included 11 secondary outcomes, including 28-day mortality.Results: As compared with standard of care alone, the proportional odds of having a higher score on the seven-point ordinal scale at day 14 was ~1.9 for the adjunct tele-yoga group (95% CI, 1.18-3.18). CRP and LDH levels were comparatively reduced in the adjunct tele-yoga group 5th day post-randomization. CRP reduction was also observed as a potential mediator for the improvement of clinical outcomes in the adjunct tele-yoga group. There were no significant differences between the treatment groups concerning the duration of hospitalization, all-cause mortality at day 28; log-rank P = 0.144, and other outcomes.Conclusion: The observed clinically relevant outcomes in COVID-19 patients at day 14 contest the use of tele-yoga as a complementary treatment in hospital settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.